BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bronte G, Cicero G, Cusenza S, Galvano A, Musso E, Rizzo S, Sortino G, Roselli M, Bazan V, Fiorentino E. Monoclonal antibodies in gastrointestinal cancers. Expert Opin Biol Ther. 2013;13:889-900. [PMID: 23441760 DOI: 10.1517/14712598.2013.774367] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Bronte G, Silvestris N, Castiglia M, Galvano A, Passiglia F, Sortino G, Cicero G, Rolfo C, Peeters M, Bazan V, Fanale D, Giordano A, Russo A. New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? Oncotarget 2015;6:24780-96. [PMID: 26318427 DOI: 10.18632/oncotarget.4959] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 9.2] [Reference Citation Analysis]
2 Galvano A, Incorvaia L, Badalamenti G, Rizzo S, Guarini A, Cusenza S, Castellana L, Barraco N, Calò V, Cutaia S, Currò G, Silvestris N, Beretta GD, Bazan V, Russo A. How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E1189. [PMID: 31443300 DOI: 10.3390/cancers11081189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Corsini LR, Fanale D, Passiglia F, Incorvaia L, Gennusa V, Bazan V, Russo A. Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. Expert Opin Drug Saf 2018;17:1197-209. [PMID: 30457416 DOI: 10.1080/14740338.2018.1550068] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Samykutty A, Shetty AV, Dakshinamoorthy G, Kalyanasundaram R, Zheng G, Chen A, Bosland MC, Kajdacsy-Balla A, Gnanasekar M. Vitamin k2, a naturally occurring menaquinone, exerts therapeutic effects on both hormone-dependent and hormone-independent prostate cancer cells. Evid Based Complement Alternat Med 2013;2013:287358. [PMID: 24062781 DOI: 10.1155/2013/287358] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
5 Markman JL, Shiao SL. Impact of the immune system and immunotherapy in colorectal cancer. J Gastrointest Oncol. 2015;6:208-223. [PMID: 25830040 DOI: 10.3978/j.issn.2078-6891.2014.077] [Cited by in F6Publishing: 59] [Reference Citation Analysis]
6 Adackapara CA, Sholl LM, Barletta JA, Hornick JL. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology. 2013;63:187-193. [PMID: 23763264 DOI: 10.1111/his.12154] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 7.3] [Reference Citation Analysis]
7 Abdul-Latif M, Townsend K, Dearman C, Shiu KK, Khan K. Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives. Cancer Treat Rev 2020;88:102030. [PMID: 32505807 DOI: 10.1016/j.ctrv.2020.102030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
8 Singh D, Dheer D, Samykutty A, Shankar R. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development. J Control Release 2021;340:1-34. [PMID: 34673122 DOI: 10.1016/j.jconrel.2021.10.006] [Reference Citation Analysis]
9 Zoratto F, Rossi L, Giordani E, Strudel M, Papa A, Tomao S. From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors. Tumour Biol 2014;35:8471-82. [PMID: 25062724 DOI: 10.1007/s13277-014-2367-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Gristina V, La Mantia M, Galvano A, Cutaia S, Barraco N, Castiglia M, Perez A, Bono M, Iacono F, Greco M, Calcara K, Calò V, Rizzo S, Incorvaia L, Lisanti MC, Santanelli G, Sardo D, Inguglia S, Insalaco L, Castellana L, Cusenza S, Pantuso G, Russo A, Bazan V. Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma. JMP 2021;2:173-96. [DOI: 10.3390/jmp2020016] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Bronte F, Bronte G, Fanale D, Caruso S, Bronte E, Bavetta MG, Fiorentino E, Rolfo C, Bazan V, Di Marco V, Russo A. HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma. Crit Rev Oncol Hematol 2016;97:312-21. [PMID: 26603462 DOI: 10.1016/j.critrevonc.2015.09.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
12 Passiglia F, Bronte G, Bazan V, Galvano A, Vincenzi B, Russo A. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016;99:150-157. [PMID: 26775732 DOI: 10.1016/j.critrevonc.2015.12.015] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 8.8] [Reference Citation Analysis]
13 Silvestris N, Vincenzi B, Brunetti AE, Loupakis F, Dell’Aquila E, Russo A, Scartozzi M, Giampieri R, Cascinu S, Lorusso V. Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. Pharmacogenomics. 2014;15:1701-1715. [PMID: 25410895 DOI: 10.2217/pgs.14.124] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
14 Gnoni A, Santini D, Scartozzi M, Russo A, Licchetta A, Palmieri V, Lupo L, Faloppi L, Palasciano G, Memeo V. Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? Expert Opin Ther Targets. 2015;19:1623-1635. [PMID: 26212068 DOI: 10.1517/14728222.2015.1071354] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
15 Bronte G, Sortino G, Passiglia F, Rizzo S, Lo Vullo F, Galvano A, Bazan V, Rolfo C, Russo A. Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario. Expert Opinion on Biological Therapy 2014;15:45-59. [DOI: 10.1517/14712598.2015.963052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
16 Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. World J Gastroenterol 2015; 21(23): 7281-7288 [PMID: 26109816 DOI: 10.3748/wjg.v21.i23.7281] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]